Confusion and Contradiction: Untangling Drug Importation and Counterfeit Drugs by Gilbert, Tim & Halwani, Sana
CONFUSION AND CONTRADICTION:
UNTANGLING DRUG IMPORTATION AND
COUNTERFEIT DRUGS
TIM GILBERT & SANA HALWANI*
INTRODUCTION
Drug importation from Canada is an issue attracting tremendous
attention in the United States. The issue of importation is intertwined
with the potential for counterfeit drugs, and several considerations re-
garding this issue deserve attention. First, drugs used in the United
States and Canada are manufactured around the world. Second, many
of the counterfeiting issues focus around entry, not at the consumer
level, but at the manufacturing or wholesale level. Finally, counterfeit
medicines are not a local or single-country problem, but a global is-
sue. Safety of the medicine supply, therefore, cannot be taken for
granted. Fundamentally, drug safety is not an importation issue, but
instead a highly complex problem of international regulation and nec-
essary harmonization. To effectively address issues of safety, and by
the same token, counterfeits and importation, there must be a closed
distribution chain without a gray market, electronic tracking and trace
security features must be implemented, and tougher penalties and bet-
ter enforcement of sanctions against counterfeiters must be put into
place.
* Tim Gilbert is a partner and founder of Gilbert's LLP, and Sana Halwani is an asso-
ciate at Gilbert's LLP. We would like to thank Nathaniel Lipkus and Victor So for research
help, as well as Shonagh McVean and David Coffin-Beach for editorial assistance and in-
sightful comments. As always, all errors remain our own.
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BACKGROUND
Drug importation first became big news in the United States when
busloads of seniors began crossing the border to buy cheaper drugs
from Canadian pharmacies.' Media reports soon followed that
Americans were buying drugs from Canadian Internet pharmacies.
Numerous bills were introduced in the House and Senate, each aimed
at creating an importation scheme for prescription drugs.2
At the same time, articles and books were being written about the
problem of counterfeit drugs in America3 and the fact that many Inter-
net pharmacies claiming to be Canadian were not in fact based in
Canada and were not selling Canadian-approved drug products. More
broadly, Americans learned that a significant portion of the drugs
available through the Internet were counterfeit.
These two stories-importation and counterfeit drugs-have now
become intertwined and inseparable. There is a growing perception
that drugs imported into the United States have a much greater chance
of being counterfeit. Underlying this belief appears to be a sort of
xenophobic sentiment, a fear of drugs that are anything but home-
grown. Yet, an important fact appears to have been forgotten: Ameri-
can drugs--drugs that are approved by the Food and Drug Admini-
stration (FDA) for sale in the United States-are manufactured all
over the world.4
1. See IMS, RETAIL PRESCRIPTIONS GROW AT RECORD LEVEL IN 2003 (2004),
http://www.imshealthcanada.con/htmen/1_09.htm. Although Food and Drug Administra-
tion (FDA) regulations currently prohibit retail pharmaceutical imports from Canada, a discre-
tionary policy of the FDA and U.S. Customs Service allows a significant volume of imports
to the United States. Total imports under the Customs Service personal use exemption totaled
approximately $600 million in 2003. Id.
2. Safe Import Act of 2005, S. 184, 109th Cong. (2005); Pharmaceutical Market Access
Act of 2005, H.R. 328, 109th Cong. (2005); Pharmaceutical Market Access and Drug Safety
Act of 2005, S. 334, 109th Cong. (2005). These three bills are currently making their way
through Congress and are commonly called the Gregg Bill (S. 184), the Gutknecht Bill (H.R.
328), and the Dorgan-Snowe Bill (S. 334). For more information on the progress of these
bills, see Thomas: Legislative Information on the Internet, http://thomas.loc.gov (insert the
above-mentioned bill numbers into a search of the 109th Congress).
3. See, e.g., KATHERINE EBAN, DANGEROUS DOSES: How COUNTERFEITERS ARE
CONTAMINATING AMERICA'S DRUG SUPPLY (2005).
4. J. Busfield, Globalization and the Pharmaceutical Industry Revisited, 33 INT'L. J.
HEALTH SERVS. 581, 593 (1998). For example, Novartis has subsidiaries, joint ventures, and
associated companies in fifty-one countries, including countries in South America, Asia, and
Africa. Id. In addition, AstraZeneca has thirty-four manufacturing sites in twenty countries
across the world, with principal manufacturing facilities in the United Kingdom, Sweden,
United States, Australia, Brazil, China, France, Germany, Italy, Japan, and Puerto Rico. Id.
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Counterfeit drugs are entering the system not only at the consumer
level, but also at the manufacturing or wholesale level.5 As Spies and
Van Dusen have explained, "[l]ower prices and easy availability are
the carrots that counterfeit drug manufacturers and distributors offer to
other wholesalers and pharmacies."6 In their article, they also state
that sixty percent of brand-name drugs originate from foreign suppli-
ers (the figure is even higher for generic products).7
Furthermore, counterfeiting is a global problem, best addressed by
global solutions. According to the World Health Organization
(WHO), approximately seven percent of the global supply of pharma-
ceuticals is believed to be counterfeit.8
The safety of the drug supply can never be taken for granted.
Even when a drug has been approved by the FDA, is being manufac-
tured in the United States, and counterfeiting is absent, safety may still
be compromised. In March of this year, the FDA recalled Paxil CR
tablets over a concern that GlaxoSmithKline's violation of manufac-
turing standards in its Puerto Rico plant "may have resulted in the
production of poor quality drug products that could potentially pose
risks to consumers."
9
This essay argues that counterfeit drugs are not an importation
problem, but rather a problem of international drug regulation and
harmonization. What is needed, therefore, is a regulatory system for
all drugs in global distribution. Such a system should contain the fol-
lowing elements: (1) a closed distribution chain without a gray mar-
ket; (2) employment of electronic track and trace technology; and (3)
implementation of tougher penalties and better enforcement. It is ob-
vious that to achieve these goals, international cooperation in the form
of standard-setting should be pursued. The drug industry would bene-
5. Alan R. Spies & Virgil Van Dusen, Counterfeit Drugs: A Menace Keeps Growing,





9. Press Release, FDA, U.S. Marshals Seize Lots of GlaxoSmithKline's Paxil CR and
Avandamet Tablets Because of Continuing Good Manufacturing Practice Violations (Mar. 4,
2005), available at http://www.fda.gov/bbs/topics/news/2005/NEW01162.html.
Among the violations noted during FDA's latest inspection was the finding that
the Paxil CR tablets could split apart and patients could receive a portion of the
tablets that lacks any active ingredient, or alternatively a portion that contains
active ingredient and does not have the intended controlled-release effect. Addi-
tionally, FDA found that some Avandamet tablets did not have an accurate dose
of rosiglitazone, an active ingredient in this product.
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fit from harmonization of drug regulation and anti-counterfeiting
measures, offences, and penalties.
Prior to exploring these proposed measures, we will discuss the
Canadian perspective; Canada being the primary source of drugs im-
ported at the consumer level, as well as the perspective of the Ameri-
can consumer on imports and counterfeit medicines.
THE CANADIAN PERSPECTIVE
The Canadian perspective on drug exports is characterized by
conflicting sentiments: defensiveness about Canadian "price controls,"
confusion about the U.S. position on Canadian drugs, pride over Can-
ada's drug regulatory system, and worries about Canada's own drug
supply.
The reason Canadian drugs are in demand is the perception that
drug prices in Canada (and abroad) are less expensive than in the
United States. Like most generalizations, this perception has been the
subject of some scrutiny; some studies support it, while others debunk
it. 10
Canada has effectively implemented price controls through the
Patented Medicine Prices Review Board (PMPRB)," and the Cana-
dian government is a major drug purchaser and uses its market power
to set prices for government drug programs.' 2 The American market
is not structured in the same way. Americans under government plans
pay the least, while those with no insurance pay the most. Accord-
ingly, uninsured senior citizens are often the ones who seek relief in
Canada.
Despite conflicting evidence regarding the precise nature of the
difference in rising numbers between domestic and foreign drug
prices, the fact remains that American citizens do import drugs from
10. See, e.g., Patricia M. Danzon & Michal F. Furukawa, Prices and Availability of
Pharmaceuticals: Evidence from Nine Countries, HEALTH AFT., Oct. 29, 2003,
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.521vl.htm; John R. Graham & Beverly
A. Robson, Prescription Drug Prices in Canada and the United States--Part 1: A Compara-
tive Survey, 42 PUB. POL'Y SOURCES 1 (2000), available at httpi/www.fraserinstitute.
ca/admin/books/files/PrDrgPrl(42).pdf.; Aidan Hollis, How Cheap are Canada's Drugs
Really?, 7 J. PHARMACY & PHARMACEUTICAL Sci. 215 (2004).
11. See generally Patented Medicines Prices Review Board Homepage,
http://www.pmprb-cepmb.gc.ca/english/home.asp?x=l (providing more information on this
quasi-judicial body).
12. Contra Office of National Drug Control Policy Reauthorization Act of 2003, S.
1860, 108th Cong. (2003) (stating that providing prescription drug benefits to uninsured
Americans prohibits the government from negotiating discounts).
4
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abroad. It appears that, for some consumers, on any given day identi-
cal brand drugs may cost less in Canada than in the United States. 3
Faced with this issue, U.S. lawmakers have turned their attention
to adopting drug importation legislation to allow Americans to import
cheaper foreign drugs. ' 4 While drug importation may not be the only,
or best, solution to the problem of providing access to affordable
medicines, it has remained an enticing policy response to provide
short-term relief to high drug price pains.
Although numerous consumer groups and many local and state
governments have lobbied for drug importation, the presidential posi-
tion on drug imports from Canada has been contradictory. In the sec-
ond presidential debate, President Bush stated: "[w]hen a drug comes
in from Canada, I want to make sure it cures you and doesn't kill
you." 5  While in the third debate he said the following: "[w]e're
working with Canada to ... help us realize the vaccine necessary to
make sure our citizens have got flu vaccinations during this upcoming
season."' 6 Governmental consensus on the safety of Canadian drugs is
therefore lacking.
A number of U.S. stakeholders have argued that the Canadian
regulatory system is as good, if not better, than the U.S. system. At
the HHS Importation Task Force Stakeholder Meeting, both Vermont
Governor Douglas and Kevin Concannon, Director of the Iowa De-
partment of Human Services, made statements to that effect. Gover-
nor Douglas stated, "[p]rescription drugs are regulated just as strictly
in Canada as they are in the United States .... The integrity of the
supply system, the distribution system in Canada for drugs equals, if
not exceeds, that in our own country." 7 Furthermore, Concannon
stated: "My impression from meeting with the regulatory agencies in
Canada, they are more stringent in terms of their pharmacy regulations
13. Graham & Robson, supra note 10. For example, this may be the case for drugs that
are reimported into the United States. The manufacturer's U.S.-based plant supplies the drug
to both the Canadian and U.S. markets. See id.
14. See generally Safe Import Act of 2005, S. 184, 109th Cong. (2005); Pharmaceutical
Market Access Act of 2005, H.R. 328, 109th Cong. (2005); Pharmaceutical Market Access
and Drug Safety Act of 2005, S. 334, 109th Cong. (2005).
15. President George W. Bush, Remarks at the Second Presidential Debate (Oct. 8,
2004) (transcript available at http://www.washingtonpost.com/wp-srv/politics/debatereferee
/debate_ 1008.html).
16. President George W. Bush, Remarks at the Third Presidential Debate (Oct. 13,
2004) (transcript available at http://www.washingtonpost.comwp-srv/politics/debatereferee/
debate_10 13.html).
17. Governor Jim Douglas (Vt.), Remarks at the U.S. Dep't of Health and Human
Servs. Importation Task Force Stakeholder Meeting (May 5, 2004) (transcript available at
http://www.hhs.gov/importtaskforce/session5/transcript.htm).
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than we are in the [United States]."18 In fact, most Canadian drugs
originate from the same sources as their U.S. counterparts. But re-
gardless of whether U.S. authorities agree that Canadian drugs are
safe, the issue of drug importation from Canada will become moot if
Canada refuses to export its drugs, which it appears has become a real
possibility.
The Canadian government has recently announced that it intends
to ban bulk exports, if necessary, to protect domestic medical supplies.
The Minister of Health, Ujjal Dosanjh, is planning on introducing leg-
islation that would ban bulk imports, which would only come into ef-
fect "in the event that there is a shortage or anticipated shortage" of
drugs in Canada. 19 Such legislation would throw a wrench into the
best-laid American plans for cheaper drug imports.
THE PERSPECTIVE OF THE AMERICAN CONSUMER
At the root of the importation debate is the drive to improve ac-
cess to affordable drugs in the United States. As DiMasi, Hansen, and
Grabowski have stated: "the congressional debates on Medicare pre-
scription drug coverage and various state initiatives to fill gaps in cov-
erage for the elderly and the uninsured have intensified the interest in
the performance of the pharmaceutical industry."" ° This point was
further emphasized in the preamble to the Dorgan-Snowe Bill, which
stated: "A prescription drug is neither safe nor effective to an individ-
ual who cannot afford it."'" Though governmental drug programs ex-
ist, these do not aid many of the uninsured Americans who struggle
when illness hits their family. As a result, these individuals take un-
necessary personal risks by ordering drugs from unaccredited Internet
pharmacies and buying drugs from less than reputable sources,
whether in the United States, Canada or Mexico. In this manner, these
individuals take on the risk of purchasing and consuming counterfeit
drugs.
18. Kevin Concannon, Remarks at the U.S. Dep't of Health and Human Servs. Importa-
tion Task Force Stakeholder Meeting (May 5, 2004) (transcript available at
http://www.hhs.gov/ importtaskforce/session5/transcript.html).
19. • Drug Supply Will Be Protected, Dosanjh Says, CANADIAN PREss, June 29, 2005,
available at http://www.theglobeandmail.com/servlet/story/RTGAM.20050629.wdrug0629/
BNStory/National/.
20. Joseph.A. DiMasi et al., The Price of Innovation: New Estimates of Drug Develop-
ment Costs, 22 J. HEALTH ECON. 151, 152 (2003).
21. Pharmaceutical Market Access and Drug Safety Act of 2005, S. 334, 109th Cong. §
2 (2005).
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Both the high prices of prescription drugs and the American pat-
ent system have been blamed for the high level of counterfeiting in the
drug industry. For example, Aidan Hollis has argued that the patent
monopoly system does not function well in the pharmaceutical indus-
try in that "it leads to misdirected innovation and marketing, to ineffi-
ciently high prices, to high volumes of counterfeit drugs, to parallel
imports, and, indirectly, to price controls."22 More specifically, he has
argued that "[t]he high prices of patented drugs compared to produc-
tion costs, and the difficulty of verifying the legitimacy of products,
have led to a flood of counterfeit medicines. Counterfeits comprise a
substantial share of the global market for pharmaceuticals."23
Low-income communities are arguably the most affected by coun-
terfeit drugs. During a HHS Importation Task Force meeting, Rene
Rodriguez stated:
Minority and low-income and other traditionally underserved popula-
tions will likely get a disproportionate share of these bad medicines.
As state Medicare programs struggle to save money, it is those who
have the least ability to pay who will be hurt the most. They will end
up with a two-tier system, where people in the suburbs get safe, FDA
medicines, and people in the bamos get medicines of unknown qual-
ity and origin.
24
Thus, high prices of prescription drugs affect the consumers in
two ways. First, consumers go elsewhere in hopes of finding a bar-
gain and buy into importation programs, whether on bus tours or
through the Internet. Second, high prices for prescription drugs only
encourage the counterfeit drug trade, which has potentially deadly ef-
fects for consumers. Therefore, current legislative efforts to legalize
importation may only provide a band-aid solution to the much deeper-
rooted issue of pricing in the drug industry.
IMPORTING WITHIN THE FDA SCHEME
Putting aside the possibility of a Canadian ban on exports and the
underlying problem of pricing and the patent system, any importation
of drugs from Canada may undermine the FDA's regulatory system.
22. Aidan Hollis, An Efficient Reward System for Pharmaceutical Innovation 4 (Jan. 1,
2005) (unpublished manuscript, http://econ.ucalgary.ca/fac-files/ah/drugprizes.pdf).
23. Id. at 6.
24. Rene Rodriguez, Remarks at the HHS Importation Task Force Public Meeting (Apr.
14, 2004) (transcript available at http://www.hhs.gov/importtaskforce/session3/tran-
script.html).
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The FDA has not explicitly made this argument, but mentions it as a
potential stumbling block to a drug importation scheme.
Under the current regulatory system, the FDA requires generic
drug manufacturers to submit studies demonstrating bioequivalence to
the U.S. reference product.25 Therefore, even if a generic drug is ap-
proved by Health Canada, the drug manufacturer may have to perform
additional bioequivalence studies because the generic drug was ap-
proved based on a different reference product than in the United
States. A Canadian generic manufacturer who wants to export Cana-
dian drugs to the United States would have to repeat studies using the
U.S. reference product. Should Canadian generic drugs be permitted
to be exported, and the FDA permit these drugs to be imported with-
out providing these studies, it will be difficult for the FDA to argue
that these same generic drugs must demonstrate bioequivalence to the
U.S. reference product to be approved by the FDA. In this manner,
the importation of these drugs will allow drug manufacturers to do an
"end run" on the current FDA regulatory scheme.
Whatever stance the FDA takes with respect to drug importation,
it must reconcile its position with U.S. treaty requirements, such as the
National Treatment and Most Favored Nation clauses under the North
American Free Trade Agreement (NAFTA).
In the NAFTA arbitral ruling in Cross-Border Trucking Ser-
vices,2 6 the panel found that "[d]ifferential treatment should be no
greater than necessary for legitimate regulatory reasons, such as
safety, and that such different treatment be equivalent to the treatment
accorded to domestic service providers."27 It may be difficult for the
FDA to maintain the requirement for additional studies in the case of
approved Canadian drugs, if these drugs are being allowed into the
United States through importation.
25. A reference product is usually a brand product on which the generic version is
based.
26. In re Cross-Border Trucking Services, N.A.F.T.A. Binat. Panel No. USA-MEX-98-
2008-01 (2001). The facts of the case were as follows: The United States banned Mexican
trucks from crossing into the United States because Mexico's truck regulatory scheme was
not at U.S. standards. Id. Mexico alleged a violation of National Treatment and Most Fa-
vored Nation clauses because of blanket prohibition and argued that Mexican trucks should be
evaluated on a truck-by-truck basis. Id.
27. Id. at 142-43.
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ENSURING SAFE IMPORTS INTO THE UNITED STATES
The WHO has found that "[p]harmaceuticals made for export are
not regulated by exporting countries to the same standards as those
produced for domestic use. In addition, pharmaceuticals are some-
times exported through free trade zones where drug control is lax and
where repackaging and re-labeling take place; this can facilitate trade
in counterfeit goods."2
It is therefore incumbent upon the importers of these drugs to as-
certain the pedigree of the drugs that are being purchased. However,
at the moment, only a handful of states have implemented a rigorous
licensing scheme for wholesale distributors.
The FDA is encouraging such efforts by the states and made state-
ments to this effect in its Annual Update on counterfeit drugs:
FDA strongly supported the efforts taken by the National Association of
Boards of Pharmacy (NABP) in revising the Model Rules for Licensure of
Wholesale Distributors for states to adopt. These Model Rules make it
difficult for illegitimate wholesalers to become licensed and then to trans-
act business. Four states have laws in place that are similar to the Model
Rules (Florida, Nevada, California, and Indiana), and other states are con-
sidering adoption (e.g., New Jersey, Iowa). FDA has provided advice and
input on a few legislative proposals and we recommend that more states29
move in this direction in the coming year.
FIGHTING COUNTERFEIT DRUGS
Apart from a rigorous regulatory system and distributor licensing
scheme, anti-counterfeiting measures are necessary to ensure a safe
drug supply.
Anti-Counterfeiting Technologies
The drug industry can learn from other industries and the meas-
ures they have instituted to fight counterfeiting. In other industries, a
robust anti-counterfeiting enforcement plan consists of three elements:
28. Dep't of Essential Drugs & Other Medicines, WHO, Counterfeit Drugs: Guidelines
for the Development of Measures to Combat Counterfeit Drugs 17, (1999), available at
http://whqlibdoc.who.int/hq/1999/ WHOEDMQSM_99. 1.pdf.
29. FDA, COMBATING COUNTERFEIT DRUGS: A REPORT OF THE FOOD AND DRUG
ADMINISTRATION ANNUAL UPDATE (2005), available at http://www.fda.gov/oc/initiatives/
counterfeit/update2005.html.
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(1) rights management technology, (2) training of public officials, and
(3) legal rights enforcement.
Rights Management Technology
Numerous measures have been implemented by various industries
to prevent counterfeiting. These include holographic labels, 3° micro-
labelling or microthreading, 31 color-shifting labels, 32 proprietary col-
ors,33 and embedded unique coding. These same measures could be
adapted to the drug industry in varying degrees, but primarily to the
packaging of drugs. All drug products and their intermediates are la-
beled and packaged, making measures such as these easily applicable
to the entire supply chain of prescription drugs.
In its report, Combating Counterfeit Drugs, the FDA concluded
that use and tamper evident packaging can be beneficial in fighting
counterfeit drugs, but that these measures can not stand alone, as they
do not present high enough hurdles for counterfeiters.34
Technology is also being developed with the pharmaceutical in-
dustry in mind. Two such technologies are radio-frequency identifica-
tion (RFID) and process analytical technology (PAT).
The FDA has advocated for the implementation of electronic track
and trace mechanisms, specifically RFID.35 In its annual update, the
FDA stated that "[o]ver the last year, stakeholders have made tremen-
dous progress in the development and implementation of EPC [elec-
tronic product code]/RFID. This is a huge endeavor that requires
close collaboration among all constituents of the pharmaceutical dis-
tribution system. We have observed and supported this collaboration,
and we continue to support it today. ' ' 36 As discussed below, the effec-
30. Copying the hologram can be prohibitively expensive for counterfeiters.
31. By placing hidden, distinctive marks on a purse, law enforcement officials can eas-
ily identify counterfeit goods by the absence of microthread patterns or microlabels.
32. For example, Epson packages its print cartridges with a color-shifting label. When
viewed through a proprietary Epson viewer, the label on the legitimate cartridge changes
color, while the label on the counterfeit cartridge remains the same.
33. For example, Nokia has registered the rights to a particular shade of blue-Nokia
Blue. They refuse to sub-license the rights, so the formula for their shade of blue is unknown
or not offered by companies that mix colors. Even when the color is known, these companies
will often shy away from authorizing infringement by helping to mix the color for would-be
counterfeiters.
34. FDA, COMBATING COUNTERFEIT DRUGS: A REPORT OF THE FOOD AND DRUG
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tive use of RFID will likely require international cooperation to ensure
that trading partners adopt technology that is compatible.
In addition to containing electronic product codes, RFID technol-
ogy could be used to contain data about the manufacturing process of
the tagged drugs.
PAT is "a system for continuous analysis and control of manufac-
turing processes based on real-time measurements ... during process-
ing, of quality and performance attributes of raw and in-process mate-
rials and processes to assure end product quality at the completion of
the process. 37 PAT is aimed at two goals: (1) improving process effi-
ciency to benefit producers, and ultimately consumers, through lower
costs; and (2) decreasing product recalls due to human error in the
manufacturing process. The FDA has published a guide for the indus-
try on PAT implementation.38
PAT could conceivably be used to prevent undetectable counter-
feit drugs from reaching the market. With PAT, manufacturers would
only be allowed to manufacture at certain times and locations and un-
der specific guidelines. Information about each batch of drugs could
be kept in a secret alphanumeric code, which counterfeiters could not
interpret. Since counterfeiters typically copy individual batches, but
do not change the codes, anti-counterfeiting efforts could be targeted
at unauthorized codes or codes which are overabundant in the mar-
ket.39 PAT could be taken one step further and managed at the unit
level. Drug companies could distribute pills in set quantities-of 20,
50, 100, etc. Each pill bottle would have a unique coding based on the
batch information authorized by the PAT system. Better supply chain
management in this regard would demonstrate to the patient that the
pill bottle has been sealed from point of manufacture all the way to the
patient's hand. However, in such a case, pharmacists would not be al-
lowed to repackage formulations, as this would provide an opportunity
to counterfeiters. 4°
37. Ajaz S. Hussain, Closing Remarks at the Meeting of the Process Analytical Tech-
nologies Subcommittee of the FDA Advisory Committee for Pharmaceutical Science (Feb.
26, 2002) (transcript available at http://www.fda.gov/ohrms/dockets/ac/02/tran-
scripts/3841 t2.pdf).
38. FDA, FDA GUIDANCE FOR INDUSTRY: PAT-A FRAMEWORK FOR INNOVATIVE
PHARMACEUTICAL DEVELOPMENT, MANUFACTURING, AND QUALITY ASSURANCE (2004), avail-
able at http://www.fda.gov/cder/guidance/6419fnl.pdf.
39. Id.
40. This approach would certainly be viewed today as a "second generation" PAT type
application. The major PAT thrust today is better process "understanding," but with advances
in PAT, this application is feasible. Id.
11
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Legal Rights Enforcement: Improving Enforcement
and Increasing Penalties
All the anti-counterfeiting technologies in the world are useless
unless they are implemented and recognized by law enforcement per-
sonnel. As law enforcement resources are limited, they are unlikely to
become informed unless manufacturers attract their attention. While
counterfeit drugs may seem like a compelling subject of police inves-
tigation, so are organized crime, sexual assault, and other serious
crimes. Therefore, training of law enforcement by drug manufacturers
in the differences between real and fake drugs is essential to any anti-
counterfeiting program. Law enforcement officials are only likely to
conduct investigations if they know how to verify their success.
As to penalties, the FDA has recommended increasing the penal-
ties for counterfeit drugs, noting "counterfeiting a prescription drug
label (bearing a registered trademark) is punishable by up to ten years
in prison, while counterfeiting the drug itself is punishable by a
maximum of only three years in prison."'"
Creating International Drug Standards
One positive development that could come from allowing the im-
portation of drugs would be increased global cooperation regarding
safety, which would in turn help to reduce counterfeiting. The Cana-
dian and U.S. governments already communicate regularly, particu-
larly in the area of product recalls. However, the dual approval proc-
ess for drugs remains a distinct challenge in both countries where the
criteria is only slightly different. Hopefully over time there will be in-
creased harmonization of standards and approval processes.
For example, the FDA has commented on the need for harmoniza-
tion of RFID technology:
A critical piece of this undertaking [the development and implementation
of RFID] is the development of standards for the type of technology to be
used and the systems for storing and sharing pedigree information. This
activity will ensure that the electronic track andtrace technologies adopted
are comprehensible and data communication systems are interoperable.
42
Regulatory harmonization is not, however, a simple project.
Countries may lack the will to bring their regulatory systems into
41. FDA, supra note 29, at 19.
42. Id.
12
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compliance with international norms. They may believe their own
system to be more effective, or simply may not have the funds to im-
plement the necessary changes. For example, the International Con-
ference on Harmonization was introduced among the United States,
Japan, and European Union's regulatory authorities and pharmaceuti-
cal trade associations fifteen years ago.43 The idea was to produce a
set of pharmaceutical development guidelines that would lead to regu-
latory approval data acceptable to all participating parties. Still, de-
spite the opportunity for radical synergy among drug approval proc-
esses, the initiative has failed to generate harmonized Good
Manufacturing Practices (GMP) guidelines44 due to countries' differ-
ing GMP codes and standards.
In the case of harmonizing anti-counterfeiting technologies, drug
companies may cry foul when they are asked to bear the costs of im-
plementing new technology, and may claim that innovation will suf-
fer. Yet, as with seat belts and air bags in the automobile industry, the
introduction of new safety standards in the drug industry is necessary
to ensure the safety of consumers.
CONCLUSION
The momentum of globalization is being felt even in the realm of
public health, and requires international cooperation to achieve na-
tional public health goals.45 There are global health problems, global
drug companies, and a global drug market. All nations demand and
require a sufficient supply of safe and effective drugs that their citi-
zens can afford. It is therefore becoming increasingly important to
implement international drug safety standards.
The reason that a discussion about drug importation inevitably in-
volves discussion of counterfeit drugs is that the U.S. and Canadian
drug safety systems are dependent on drugs receiving approval from
the relevant national regulatory body-the FDA or Health Canada. It
is this seal of approval from highly respected agencies that both gov-
ernments should jealously guard. But banning importation on its own
43. See generally REGULATIONS WITH IMPACT ON ANALYTICAL LABORATORIES,
INTERNATIONAL CONFERENCE ON HARMONIZATION, http://www.labcompliance.com/regula-
tions/ich.htm (providing additional information on how the ICH has impacted the pharmaceu-
tical drug industry).
44. GMP is a framework of principles under which pharmaceutical manufacturing is
performed. Europe recognizes the legitimacy of Canadian GMP, but not U.S. GMP.
45. Allyn L. Taylor, Governing the Globalization of Public Health, 32 J.L. MED. &
ETHICS 500, 501 (2004).
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will not stop the problem of counterfeit drugs. Governments must act
now to effectively implement self-help measures to make counterfeit-
ing as difficult as it is in the world of currency. 46 In addition, the
pharmaceutical drug industry must realize its role in protecting the
public against counterfeit drugs. Finally, the punishment must fit the
crime; counterfeiters should be subject to stiff penalties and substan-
tial fines, as well as an anti-counterfeiting infrastructure which will
discourage this pernicious form of profit-making at patients' expense.
46. Spies & Van Dusen, supra note 5.
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